Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with alopecia areata and androgenetic alopecia showed increased c-kit expression and decreased Ki-67 expression in hair follicle cells compared to controls, suggesting a possible feedback mechanism involving stem cell factor signaling.

This study reports that pediatric alopecia areata in Faisalabad predominantly affects boys, often involves the scalp, and is significantly associated with family history of psoriasis and atopic disorders.

This study shows that in a mouse model of Alopecia Areata, selective JAK1 inhibition facilitated hair regrowth and inflammation resolution while potentially offering a better safety profile compared to pan-JAK inhibition.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Upadacitinib effectively treated severe hair loss in a child.

This study suggests that the "spade sign" is a highly specific histopathologic feature of acne keloidalis, although its absence does not rule out the condition.

This report presents a case of acrodermatitis enteropathica in a 22-year-old female, highlighting the absence of underlying comorbid conditions.

In this real-world study, JAK inhibitors like abrocitinib and tofacitinib led to substantial hair regrowth in 61% of alopecia areata patients over a median of 16 months, with 75% of non-responders achieving regrowth after switching medications; however, two serious adverse events were noted.

This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This study found that men with Kennedy disease have a significantly lower risk of androgenetic alopecia, likely due to androgen receptor gene alterations from the disease's polyglutamine expansion.

This case report of an infant with AEC syndrome highlights the importance of early and aggressive management of ocular complications to preserve vision and reduce the risk of amblyopia.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

In this study, researchers found potential evidence of inducible skin-associated lymphoid tissue (iSALT) in alopecia areata patients undergoing topical immunotherapy, which may suggest an essential role in treatment efficacy.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

In this study, patients with alopecia areata indicated a preference for shared decision-making (SDM) with their dermatologists, and those who engaged in SDM reported less decisional regret about their treatment choices.

In this case report, a 37-year-old patient with APECED showed significant clinical improvement, including hair regrowth and resolution of skin issues, after 11 months of treatment with ruxolitinib, highlighting the potential of JAK inhibitors in managing this complex autoimmune disease.

This study outlines the clinical features of androgenetic alopecia in Korean adolescents, finding milder symptoms compared to adults and a high occurrence of family history, with normal hormone levels.

This review discusses the FDA-approved JAK inhibitor baricitinib as a treatment for alopecia areata, highlighting its dosing regimen, clinical challenges, and the need for additional safety data while exploring the potential of other topical and sublingual JAK inhibitors under investigation.

This review highlights that acne keloidalis nuchae notably affects men with afro-textured hair and results in scarring and hair loss, underscoring the need for improved diagnosis and treatment strategies due to its significant psychosocial impact and high recurrence rates following current therapies.

This study found that JAK inhibitor treatment in patients with alopecia areata was associated with a lower incidence of major depressive disorder and decreased antidepressant usage.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

This case report describes a child with acrodermatitis enteropathica showing dramatic improvement with oral zinc therapy, highlighting the importance of early diagnosis and treatment to prevent severe outcomes.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This study found that inhibiting the ATR kinase with VE-822 impairs DNA repair capability in quiescent human keratinocytes exposed to solar-simulated UV radiation, suggesting ATR's critical role in facilitating effective DNA damage repair and cellular recovery under UV stress conditions.

This report reviews the clinical presentation and genetic aspects of a case of acrodermatitis enteropathica in a one-year-old child but provides no new clinical findings.

This study found that androgen inactivation pathways in scalp sebaceous glands change with age, specifically noting that AKR1C expression, including AKR1C4 previously thought liver-specific, declines with age and is sex dependent, which could impact hair follicle health during aging.